EchoStar Corporation Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? EchoStar Corporation Common Stock trades at $87 (market cap $26.63B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: EchoStar Corporation Common Stock is far larger — about 18× uniQure N.V. Ordinary Shares's market cap, and EchoStar Corporation Common Stock is more actively traded (2,918,300 versus 2,488,780). Which is the better fit depends on your goals — on Pluang, investors hold EchoStar Corporation Common Stock for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ECHO | QURE | |
|---|---|---|
Market Cap | $26.63B | $1.48B |
Volume | 2,918,300 | 2,488,780 |
Sector | Media | Health |
52-Week High | $141.80 | $70.59 |
52-Week Low | $66.93 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $43.68B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
ECHO trades at $91.56, down 3.72% over 24 hours, with a neutral technical signal and mixed earnings history including a significant Q2 2026 beat. The company reported a net loss of $14.50 billion in 2025, with negative cash flows, though revenue remains substantial at $15.00 billion. Recent news highlights institutional investments and a strategic partnership with United Airlines for in-flight streaming.
Analyst consensus is strongly bullish with a $134.00 price target, but high risks stem from persistent losses, negative cash flow, and the Hughes unit's bankruptcy. The stock's appeal hinges on turnaround execution and debt reduction efforts outweighing fundamental weaknesses.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.
Read more on ECHO →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →